Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: A study on 331 patients from a single institution

Leukemia

Volumn 19, Issue 8, 2005, Pages 1424-1431

  Bernasconi, P ^a   Klersy, C ^b   Boni, M ^a   Cavigliano, P M ^a   Calatroni, S ^a   Giardini, I ^a   Rocca, B ^a   Zappatore, R ^a   Caresana, M ^a   Quarna, J ^a   Lazzarino, M ^a   Bernasconi, C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chromosome abnormalities; IPSS; Karyotype; MDS; Prognostic scores

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 7; CLINICAL FEATURE; CYTOPENIA; DISEASE COURSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KARYOTYPING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS;

EID: 23744513172     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403806     Document Type: Article

References (40)

1. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998; 83: 71-86.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR et al. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
3. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol 1996; 33: 127-138.
4. Jotterand M, Parlier V. Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leukemia and Lymphoma 1996; 23: 253-266.
5. Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Hematol 2001; 14: 479-495.
6. Tricot G, Boogaerts MA, De Wolf-Peeters C, van den Berghe H, Verwilghen RL. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations. Br J Haematol 1985; 59: 659-670.
7. Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68: 189-194.
8. Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67: 1765-1772.
9. Pierre RV, Catovsky D, Mufti GJ, Swansbury GJ, Mecucci C, Dewald GW et al. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 1989; 40: 149-161.
10. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425-433.
11. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
12. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia 1992; 6: 52-59.
13. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 9: 1315-1323.
14. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H et al. Clinical implications of chromosome abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7: 499-508.
15. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
16. Mitelman F (ed) ISCN: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 1995.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Statisti Assoc 1958; 53: 457-481.
18. Suciu S, Kuse R, Weh HJ, Hossfeld DK. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990; 44: 15-26.
19. Solè F, Prieto F, Badia L, Woessner S, Florensa L, Caballin MR et al. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 1992; 64: 12-20.
20. Parlier V, van Melle G, Beris P, Schmidt PM, Tobler A, Haller E et al. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet 1994; 78: 219-231.
21. Bernasconi P, Alessandrino EP, Boni M, Bonfichi M, Morra E, Lazzarino M et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival. Am J Hematol 1994; 46: 270-277.
22. Haase D, Fonatsch C, Freund M, Wörmann B, Bodenstein H, Bartels H et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995; 70: 171-187.
23. Pfeilstöcker M, Reisner R, Nösslinger T, Grüner H, Nowotny H, Tüchler H et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single intitution confirms the importance of cytogenetics. Br J Haematol 1999; 106: 455-463.
24. Solè F, Espinet B, Sanz G, Cervera J, Calasanz MJ, Luno E et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000; 108: 346-356.
25. Nösslinger T, Reisner R, Koller E, Grüner H, Tüchler H, Nowotny H et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98: 2935-2941.
26. Mauritzson N, Johansson B, Rylander L, Albin M, Strömberg U, Billström R et al. The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex. Br J Haematol 2001; 113: 347-356.
27. Nevill T, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910-1917.
28. Oosterveld M, Wittebol SH, Lemmens WA, Kiemeney BA, Catik A, Muus P et al. The impact of intensive antileukemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol 2003; 123: 81-89.
29. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposal for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983-992.
30. Zhao WL, Xu L, Wu W, Tang W, Hu J, Chen Y et al. The myelodysplastic syndromes. Analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. Hematol J 2002; 3: 137-144.
31. Washington LT, Doherty D, Glassman A, Martins J, Ibrahim S, Lai R. Myeloid disorders with deletion 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. Leukemia Lymphoma 2002; 43: 761-765.
32. Giagounidis AAN, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004; 18: 113-119.
33. Èermàk J, Michalova K, Bøezinovà J, Zemanova Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 2003; 27: 221-229.
34. Pedersen B. 5q-: does longer survival of female patients explain the preponderance. Anticancer Res 1997; 17: 3281-3285.
35. Dewald GW, Davis MP, Pierre RV, O'Fallon JR, Hoagland HC. Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood 1985; 66: 189-197.
36. Pedersen B, Jensen M. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia 1991; 5: 52-59.
37. Pasquali F, Bernasconi P, Casalone R, Fraccaro M, Bernasconi C, Lazzarino M et al. Pathogenetic significance of 'pure' monosomy 7 in myeloproliferative disorders. Analysis of 14 cases. Hum Genet 1982; 62: 40-51.
38. Velloso ER, Michaux L, Ferrant A, Hernandez JM, Meeus P, Dierlam J et al. Deletions of the long arm of chromosome 7 in myeloid disorders:loss of band 7q32 implies worst prognosis. Br J Haematol 1996; 92: 574-581.
39. Johnson E, Cotter FE. Monosomy 7 and 7q- associated with myeloid malignancy. Blood Rev 1997; 11: 46-55.
40. Le Beau MM, Espinosa III R, Davis EM, Eisenbart JD, Larson RA, Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996; 88: 1930-1935.